Navigation Links
Reportlinker Adds US and European Radiopharmaceuticals Market Report
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

US and European Radiopharmaceuticals Market

http://www.reportlinker.com/p0109914/US-and-European-Radiopharmaceuticals-Market.html

This report analyzes the US and the European markets for Radiopharmaceuticals in Millions of US$. The major product segments analyzed are Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. Annual forecasts are provided for each region for the period of 2006 through 2015. A six-year historic analysis is also provided for these markets with annual market analytics. The report profiles 82 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bio-Nucleonics, Inc., Bracco Diagnostics, Inc., Cardinal Health, Inc., Cellectar, LLC., Cell Therapeutics, Inc., Covidien Imaging Solutions, Cytogen Corporation, Draximage Inc, GE Healthcare Limited, GlaxoSmithKline Plc, IBA Molecular North America, Inc., Immunomedics, Inc., Kimberly-Clark, Inc., Lantheus Medical Imaging, Inc, MDS Nordion, Molecular Insight Pharmaceuticals, Inc., Peregrine Pharmaceuticals, Inc., PETNET Pharmaceuticals, Inc., Pharmalucence, Inc., and Triad Isotopes, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

RADIOPHARMACEUTICALS

A US & EUROPEAN MARKET REPORT MCP-1889

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Quantitative Techniques & Analytics I-3

Product Definitions and Scope of Study I-3

A. Diagnostic Radiopharmaceuticals I-3

B. Therapeutic Radiopharmaceuticals I-4

II. A US & EUROPEAN MARKET REPORT

1. Industry Overview II-1

A Quick Primer II-1

Key Market Trends II-1

Continuous Battle Against Cancer: A Key Driver for Growth II-1

Cancer Statistics: A Grim Prognosis II-1

Business Case for Radiopharmaceuticals Exemplified II-1

Development of Newer Diagnostic Agents to Boost Growth II-2

Demographics & New Applications Offer Opportunities On a Platter II-2

Recognition of Intrinsic Cost Benefits: Critical to Market

Acceptance II-2

Widespread Awareness Among Practitioners & Patients: The Need

of the Hour II-2

Expansion of Molecular Imaging Platform is Key to Future Growth II-3

Molecular Imaging Agents: A Noteworthy Breakthrough II-3

Growing Demand for PET to Drive Up Demand II-4

Introduction of SPECT/CT & PET/CT: Double Edged Weapons for

Growth II-4

Manufacturers Quick to Take Cue II-5

Promising Developments in Therapeutic Radiopharmaceuticals

Underway II-5

Targeted Peptides & Alpha Emitters: The New Frontiers of

Therapeutic Radiopharmaceuticals II-5

International Collaborations Give a Thumbs Up to Drug

Development II-6

Market Challenges II-6

High Costs of Drug Development Piques Manufacturers II-6

Supply Shortages: A Niggling Cause of Concern II-6

Price Sensitivity & Competition from Alternatives Limit

Market Potential II-7

Lack of Dosage Standards for Pediatric Patients' Limits

Radiopharmaceutical Efficacy II-7

Unfounded Fears of Radiation Exposure Hinder Growth II-7

Bottlenecks in Developing Markets II-7

Market Share Statistics: In Retrospect II-8

Table 1: Global Market for Medical Diagnostics Imaging

(2003): Percentage Share Breakdown of Value Sales by Leading

Players - GE (Amersham), Schering, Daiichi, Bristol Myers

Squibb, Mallinckrodt, Bracco, Guerbet, and Others (includes

corresponding Graph/Chart) II-8

Table 2: Global Market for Radiopharmaceutical Medical

Diagnostics (2003): Percentage Revenue Market Share of

Leading Players - Amersham, Bristol-Myers Squibb, Tyco/

Mallinckrodt, Inc and Others (includes corresponding

Graph/Chart) II-8

Table 3: Global Market for Radioimmunotherapy Products

(2003): Percentage Share Breakdown of Value Sales of Zevalin

and Bexxar II-8

2. Product Overview II-9

Nuclear Medicine: A Prelude II-9

Radiopharmaceuticals: A Definition II-9

Mechanism of Action II-9

Application of Radiopharmaceuticals II-10

Classification of Radiopharmaceuticals II-10

Diagnostic Radiopharmaceuticals II-10

Commonly Used Diagnostic Radiopharmaceutical Agents II-11

Major Isotopes and their Diagnostic Applications II-11

Advantages II-12

Classification II-13

Fluorodeoxy Glucose (FDG): A Rapidly Growing Diagnostic

Radiopharmaceutical II-13

Molecular Imaging Modalities In Radiopharmaceutical Diagnostics II-13

Planar Imaging II-13

PET: A Prime Growth Driver for FDG II-14

Advantages II-14

Applications of PET II-15

Commonly used Radioisotopes in PET Scans II-15

Major PET Isotopes and their Applications II-15

Single Photon Emission Computed Tomography (SPECT) II-16

Applications of SPECT II-17

Commonly used Radioisotopes in SPECT Scans II-17

Therapeutic Radiopharmaceuticals II-17

Characteristics of Therapeutic Radiopharmaceuticals II-17

Commonly used Therapeutic Agents II-18

Major Isotopes and their Therapeutic Applications II-18

Radiopharmaceuticals for Thyroid Therapy II-18

Radiopharmaceuticals for Cancer Therapy II-18

Radiopharmaceuticals for Radiosynoviorthesis Therapy II-18

Radiopharmaceuticals for Bone Pain Palliation Therapy II-19

A Peek Into Key Therapeutic Radiopharmaceuticals in Research

Pipeline As of the Year 2007 II-19

Radiopharmacy: A Key Link in the Distribution Chain II-20

3. Regional Market Overview II-21

3a. The United States II-21

A.Market Analysis II-21

Outlook II-21

Industry Structure II-21

Production Scenario II-21

Dependence On Imports II-21

Regulatory Scenario II-22

Thorny Regulations Dampen Down New Product Development II-22

FDA's Antidote II-22

Radiopharmaceutical Reimbursement in the US: Who's Under

the Umbrella II-23

Diagnostic Radiopharmaceuticals Bundled As Supplies Under

Medicare Reimbursements II-23

CMS Proposed Packaging of Zevalin & Bexxar into Diagnostic

Radiopharmaceuticals Raises Eyebrows II-23

Implications II-23

Recommendations II-24

Changes in Medicare Reimbursements Vetoed II-24

CMS Proposes New HOPPS Guidelines for 2008 II-25

(i) Bundling Radiology Drugs and Services II-25

(ii) Payment for Therapeutic Radiopharmaceuticals II-25

(iii) PET/CT scans II-26

(IV) Cardiac CT and Coronary CTA Procedures II-26

(v) Conversion factor II-26

Reimbursement Issues for PET II-26

PET Clinical Applications Reimbursed by CMS as of March 2008 II-27

Deficit Reduction Act (DRA) 2005: Creating a Storm in a Teacup II-28

Impact of the DRA On Outpatient Imaging Centers: An

Evaluation II-29

Market Overview II-29

Sanguine Growth On Cards II-29

Expanding Diagnostic Applications Will Stimulate Future Growth II-30

Nuclear Cardiology Products Drive Up Diagnostic

Radiopharmaceuticals Market II-30

Cardiovascular Imaging To Lead Volume Growth II-30

Table 4: US Diagnostic Radiopharmaceutical Agents Market

(2007 & 2009): Breakdown of Procedure Volume By Imaging

Procedure - SPECT (Cardiac, Others) and PET (In Thousands)

(includes corresponding Graph/Chart) II-30

Table 5: US Market for Diagnostic Radiopharmaceuticals

Agents (2008 & 2012): Percentage Share Breakdown of Value

Sales for Cardiology and Non-Cardiology Applications II-31

Table 6: US Market for Cardiology Diagnostic

Radiopharmaceuticals (2004 & 2007): Percentage Share

Breakdown of SPECT Myocardial Perfusion Imaging (MPI)

Procedure Volume by Imaging Agent - Cardiolite, Myoview

and Others (includes corresponding Graph/Chart) II-31

New Oncology, Neurology Agents to Boost Diagnostic

Radiopharmaceuticals Market II-31

Table 7: US Market for Non-Cardiology Diagnostic

Radiopharmaceuticals Agents (2007 & 2009): Percentage

Share Breakdown of Value Sales for Oncology and

Non-Oncology Applications II-32

Price Erosion to Increase Installed Base of SPECT Scanners II-32

Table 8: Diagnostic Radiopharmaceutical Market in North

America: Installed Base for SPECT and SPECT/CT Scanners in

Units for Years 2006, 2008, 2010, 2012 & 2014 (includes

corresponding Graph/Chart) II-32

Installed Pet Scanners in US II-32

US FDG Market II-33

Table 9: US FDG Market (2007 & 2009): Breakdown of

Procedure Volume by Procedure Type - Oncology, Neurology

and Cardiology (In 000s) (includes corresponding

Graph/Chart) II-33

Table 10: US FDG Radiopharmacy Market: Number of Doses,

Unit Cost and Number of Nuclear Pharmacies for 2004, 2008 &

2012(P) (includes corresponding Graph/Chart) II-33

Focused R&D Efforts will Fuel Therapeutic

Radiopharmaceuticals Market II-34

Market Share Statistics II-34

Table 11: US Market for Diagnostics Radiopharmaceuticals

Agents (2007): Percentage Share Breakdown of Value Sales by

Leading Players - Lantheus Medical Imaging, GE HealthCare,

Mallinckrodt and Others (includes corresponding

Graph/Chart) II-34

Table 12: US Market for Cardiology Diagnostic

Radiopharmaceutical Agents (2007): Percentage Share

Breakdown of Value Sales by Leading Players - Lantheus

Medical Imaging, GE HealthCare and Others (includes

corresponding Graph/Chart) II-34

Table 13: US Market for Non-Cardiology Diagnostic

Radiopharmaceutical Agents (2007): Percentage Share

Breakdown of Value Sales by Leading Players - Mallinckrodt,

GE HealthCare, Lantheus Medical Imaging and Others

(includes corresponding Graph/Chart) II-35

Table 14: US Market for Therapeutic Radiopharmaceuticals

(2007): Percentage Share Breakdown of Value Sales by Key

Radiotherapeutics - Bone Palliation, Non-Hodgkin's

Lymphoma, Hyperthyroidism /Thyroid Cancer and Others

(includes corresponding Graph/Chart) II-35

Table 15: US Market for Therapeutic Radiopharmaceutical

Agents (2007): Percentage Share Breakdown of Value Sales by

Leading Players - GE HealthCare, Mallinckrodt, Biogen-Idec,

GlaxoSmithKline, Cytogen and Others (includes corresponding

Graph/Chart) II-36

Table 16: US FDG Market (2007): Percentage Share Breakdown

of Leading Players by Number of Cyclotrons Operated -

PETNet Solutions, Cardinal Health, IBA Molecular, Triad

Isotopes and Others (includes corresponding Graph/Chart) II-36

Table 17: US Market for Radiopharmaceutical Bone Palliation

Procedures (2005): Percentage Share Breakdown by Key

Radiotherapeutics - Metastron, Quadramet and Sr-89

(includes corresponding Graph/Chart) II-36

Radiopharmaceuticals Market - A Peek Into the Recent Past II-37

Table 18: US Market for Diagnostics Radiopharmaceuticals in

the Recent Past (2001): Percentage Share Breakdown of Value

Sales by Leading Players -Bristol Meyers Squibb (DuPont),

Amersham, Mallinckrodt and Others (includes corresponding

Graph/Chart) II-37

Table 19: US Market for Cardiology Diagnostics

Radiopharmaceuticals in the Recent Past (2001): Percentage

Share Breakdown of Value Sales by Leading Players -Bristol

Meyers Squibb (DuPont), Amersham, and Others (includes

corresponding Graph/Chart) II-37

Table 20: US Market for Therapeutic Radiopharmaceuticals in

the Recent Past (2001): Percentage Share Breakdown of Value

Sales by Leading Players - Amersham, Berlex Laboratories,

Mallinckrodt and Others (includes corresponding

Graph/Chart) II-37

Table 21: US Market for Radiopharmaceuticals in the Recent

Past (2001): Percentage Share Breakdown of Value Sales by

Diagnostic Procedures -Heart Imaging Procedures, Cancer

Imaging Procedures and Neurological &Other Imaging

Procedures (includes corresponding Graph/Chart) II-38

Table 22: Radiopharmacy Market in the US (2001, 2003 &

2005): Percentage Breakdown of Revenues Generated by

General Radiopharmacies and FDG Radiopharmacies (includes

corresponding Graph/Chart) II-38

Table 23: US Market for Radiopharmacies in the Recent Past

(2001): Percentage Share Breakdown of Value Sales by

Leading Players - Syncor, Mallinckrodt, Central Pharmacy

Services Inc, Amersham and Independents (includes

corresponding Graph/Chart) II-39

B.Market Analytics II-39

Table 24: US Recent Past, Current & Future Analysis for

Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) II-39

Table 25: US Historic Review for Radiopharmaceuticals for

Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2005 (includes corresponding

Graph/Chart) II-40

Table 26: US 10-Year Perspective for Radiopharmaceuticals by

Product Segment - Percentage Breakdown of Value Sales for

Diagnostic Radiopharmaceuticals and Therapeutic

Radiopharmaceuticals for Years 2006, 2009 & 2015 II-40

3b. Europe II-41

A.Market Analysis II-41

Outlook II-41

Competitive Scenario II-41

Key Statistics II-41

Table 27: European Diagnostic Radiopharmaceuticals Market:

Percentage Share Breakdown of Value Sales by Imaging

Modalities - SPECT and PET for Years 2005, 2008 & 2012

(includes corresponding Graph/Chart) II-41

Market Trends II-41

New Applications and Products Augur Good Market Prospects II-41

Increasing PET and PET/CT Applications Will Kindle Growth II-42

B.Market Analytics II-42

Table 28: European Recent Past, Current & Future Analysis

for Radiopharmaceuticals by Geographic Region - France,

Germany, Italy, UK, Spain, and Rest of Europe Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2006 through 2015 (includes corresponding Graph/Chart) II-42

Table 29: European Historic Review for Radiopharmaceuticals

by Geographic Region - France, Germany, Italy, UK, Spain,

and Rest of Europe Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2000 through 2005 (includes

corresponding Graph/Chart) II-43

Table 30: European Recent Past, Current & Future Analysis

for Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) II-43

Table 31: European Historic Review for Radiopharmaceuticals

by Product Segment - Diagnostic Radiopharmaceuticals and

Therapeutic Radiopharmaceuticals Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2005 (includes corresponding Graph/Chart) II-44

Table 32: European 10-Year Perspective for

Radiopharmaceuticals by Geographic Region - Percentage

Breakdown of Value Sales for France, Germany, Italy, UK,

Spain, and Rest of Europe Markets for Years 2006, 2009 &

2015 (includes corresponding Graph/Chart) II-44

Table 33: European 10-Year Perspective for

Radiopharmaceuticals by Product Segment - Percentage

Breakdown of Value Sales for Diagnostic Radiopharmaceuticals

and Therapeutic Radiopharmaceuticals for Years 2006, 2009 &

2015 II-45

3ba. France II-46

A.Market Analysis II-46

Outlook II-46

B.Market Analytics II-46

Table 34: French Recent Past, Current & Future Analysis for

Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) II-46

Table 35: French Historic Review for Radiopharmaceuticals by

Product Segment - Diagnostic Radiopharmaceuticals and

Therapeutic Radiopharmaceuticals Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2005 (includes corresponding Graph/Chart) II-47

Table 36: French 10-Year Perspective for

Radiopharmaceuticals by Product Segment - Percentage

Breakdown of Value Sales for Diagnostic Radiopharmaceuticals

and Therapeutic Radiopharmaceuticals for Years 2006, 2009 &

2015 II-47

3bb. Germany II-48

A.Market Analysis II-48

Outlook II-48

B.Market Analytics II-48

Table 37: German Recent Past, Current & Future Analysis for

Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) II-48

Table 38: German Historic Review for Radiopharmaceuticals by

Product Segment - Diagnostic Radiopharmaceuticals and

Therapeutic Radiopharmaceuticals Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2005 (includes corresponding Graph/Chart) II-49

Table 39: German 10-Year Perspective for

Radiopharmaceuticals by Product Segment - Percentage

Breakdown of Value Sales for Diagnostic Radiopharmaceuticals

and Therapeutic Radiopharmaceuticals for Years 2006, 2009 &

2015 II-49

3bc. Italy II-50

A.Market Analysis II-50

Outlook II-50

B.Market Analytics II-50

Table 40: Italian Recent Past, Current & Future Analysis for

Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) II-50

Table 41: Italian Historic Review for Radiopharmaceuticals

by Product Segment - Diagnostic Radiopharmaceuticals and

Therapeutic Radiopharmaceuticals Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2005 (includes corresponding Graph/Chart) II-51

Table 42: Italian 10-Year Perspective for

Radiopharmaceuticals by Product Segment - Percentage

Breakdown of Value Sales for Diagnostic Radiopharmaceuticals

and Therapeutic Radiopharmaceuticals for Years 2006, 2009 &

2015 II-51

3bd. United Kingdom II-52

A.Market Analysis II-52

Outlook II-52

Market Overview II-52

B.Market Analytics II-52

Table 43: UK Recent Past, Current & Future Analysis for

Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) II-52

Table 44: UK Historic Review for Radiopharmaceuticals by

Product Segment - Diagnostic Radiopharmaceuticals and

Therapeutic Radiopharmaceuticals Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2005 (includes corresponding Graph/Chart) II-53

Table 45: UK 10-Year Perspective for Radiopharmaceuticals by

Product Segment - Percentage Breakdown of Value Sales for

Diagnostic Radiopharmaceuticals and Therapeutic

Radiopharmaceuticals for Years 2006, 2009 & 2015 II-53

3be. Spain II-54

A.Market Analysis II-54

Outlook II-54

B.Market Analytics II-54

Table 46: Spanish Recent Past, Current & Future Analysis for

Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2006 through 2015 (includes corresponding

Graph/Chart) II-54

Table 47: Spanish Historic Review for Radiopharmaceuticals

by Product Segment - Diagnostic Radiopharmaceuticals and

Therapeutic Radiopharmaceuticals Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2000 through

2005 (includes corresponding Graph/Chart) II-55

Table 48: Spanish 10-Year Perspective for

Radiopharmaceuticals by Product Segment - Percentage

Breakdown of Value Sales for Diagnostic Radiopharmaceuticals

and Therapeutic Radiopharmaceuticals for Years 2006, 2009 &

2015 II-55

3bf. Rest of Europe II-56

A.Market Analysis II-56

Outlook II-56

Market Overview II-56

B.Market Analytics II-56

Table 49: Rest of Europe Recent Past, Current & Future

Analysis for Radiopharmaceuticals by Product Segment -

Diagnostic Radiopharmaceuticals and Therapeutic

Radiopharmaceuticals Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2006 through 2015

(includes corresponding Graph/Chart) II-56

Table 50: Rest of Europe Historic Review for

Radiopharmaceuticals by Product Segment - Diagnostic

Radiopharmaceuticals and Therapeutic Radiopharmaceuticals

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2000 through 2005 (includes corresponding

Graph/Chart) II-57

Table 51: Rest of Europe 10-Year Perspective for

Radiopharmaceuticals by Product Segment - Percentage

Breakdown of Value Sales for Diagnostic Radiopharmaceuticals

and Therapeutic Radiopharmaceuticals for Years 2006, 2009 &

2015 II-57

4. Research & Development Breakthroughs II-58

Azaya, Texas University Collaborate for Liposomal Radiation

Therapy II-58

Pharmacyclics Reveals Phase 1/2 Study of MGd Antibody Targeted

Radiation Therapy II-58

Peregrine Explores Potential of Cotara(R) for Brain Cancer

Treatment II-58

Scientists Develop New Manufacturing Technology For Cancer

Diagnostic Radioisotopes II-58

Avid Radiopharmaceuticals Exploits ExpIND to Speed AD Drug

Research II-59

Scientists Commend Combination Therapy for Follicular Lymphoma

Patients II-59

Missouri University Develops New Cancer Radiotherapy Method II-60

AGH Researchers Develop New Radioactive Seed Therapy for Lung

Cancer II-60

AnazaoHealth(R) Obtains US Patent for Novel Radiopharmaceutical

Preparations II-60

INMAS Develops Ciprofloxacin Radiolabelling Kit II-60

5. Product Innovations/Introductions II-61

Medrad Mounts Intego(TM) PET Infusion System at UPMC II-61

IBA Molecular Announces the Launch of Cyclone (R) 18 Twin II-61

Immunomedics Announces Pre-Clinical Results for its

Combination Radioimmunotherapy II-61

Molecular Insight Develops New Radioiodinated Molecules II-61

Immunomedics Develops New Antibody for Radioimmunotherapy II-61

Peregrine Pharmaceuticals Launches Anti-Cancer Agent in China II-62

GE Healthcare Introduces Proton Package For Radiation Therapy

Planning II-62

GE Healthcare Expands Definium Series of Digital Radiographic

Products II-62

GE Introduces New Platform for PET Radiopharmaceutical Production II-62

Draximage Gains FDA Approval for HiCon Kit II-63

Nihon Medi-Physics Secures Production Approval for FDG Scan

Injection II-63

FDA Proposes Rules and Regulations with Respect to Radioactive

Drugs II-63

Schering Nordiska Launches Zevalin Radioimmunotherapy in Europe II-63

Immunomedics Announces Advancement in Radioimmunotherapy

Technology II-64

Nihon Launches Radiopharmaceutical Agent for Enabling Epilepsy

Diagnosis II-64

6. Recent Industry Activity II-65

Positron Concludes Dose Shield Acquisition II-65

Positron Licenses NuView to Sell Imaging Technologies and Dose

Dispensing Devices II-65

Bracco Imaging, Marillion Pharmaceuticals to Develop Novel

Cancer Treatment II-65

EUSA Pharma Concludes Cytogen Acquisition II-65

AMIC, CRS to Co-Produce Indium-111 II-65

AMIC, MU Partner to Produce Radioisotopes II-66

Bracco, Lantheus to Co-Promote CardioGen-82(R) II-66

Cell Therapeutics Submits sBLA for Use of Zevalin(R) in First-

Line Therapy II-66

ANSTO, Siemens Ink $10m Partnership Deal II-66

Covidien Gets FDA Nod for Generic Myocardial Perfusion Imaging

Kit II-66

Neoprobe, Draximage Collaborate Over Lymphoseek Distribution II-66

GE Healthcare Gets FDA Nod For New PET/CT Scanner II-67

GE Healthcare, Gamma Medica-Ideas Ink Distribution Deal II-67

CIS-US Receives FDA Approval for Generic Choletec(R) Kit II-67

Cellectar Obtains Funds for Clinical Trials II-67

Lantheus Medical Completes Phase I Study Of Novel PET Imaging

Tracer II-67

GE Healthcare, Cardinal Health Partner for Myoview(TM) Imaging Agent II-67

Avista Capital Partners Acquires Medical Imaging Unit of

Bristol-Myers II-68

Siemens Healthcare Opens Two Radiopharmacies in US II-68

Cardinal Health Plans to Offer Services to Support PET

Clinical Trials II-68

MEDRAD Associates with PETNET to Ingeniously Deliver FDG II-68

Triad Isotopes to Build Four Nuclear Pharmacies II-69

AREVA, NCI to Develop Cancer-fighting Radiopharmaceuticals II-69

NuView Signs Agreement with California University II-69

NuView Inks Exclusive Agreement with Philadelphia's Jefferson

University II-69

University of Missouri Health Care Enters Sole-Source Supply

Contract with Mid-America Isotopes II-69

Cardinal Health Expands Manufacturing Capabilities for PET

Imaging Agents II-70

Jubilant Completes Draxis Acquisition II-70

Atomic Energy Closes Two Reactors II-70

IBA Plans to Acquire CIS BIO II-70

Ion Beam Announces Closure of TAEK Financing II-70

IBA Receives Approval for New Radiopharmaceutical Production

Facility in UK II-71

WILEX AG Signs Licensing and Marketing Deal with Ion Beam II-71

Ion Beam Partners with Lantheus to Distribute Neurolite(R),

Cardiolite(R) in Europe II-71

EIS Eczacibasi to Acquire 50 Percent Stake in Monrol II-72

Siemens to Set up Multiple Radiopharmaceutical Facilities in

India II-72

Siemens Plans to Establish Its First Molecular Imaging Centre

in India II-72

Ion Beam, Hae Dong Expands South Korea's PET

Radiopharmaceutical Market II-72

Bayer and FutureChem Enter Radiolabeling Technology Licensing

Agreement II-73

Cyclopharm Signs Agreement to Establish PET Radiopharmacy II-73

R2 Solucoes to Produce FGD-18, Radiological Diagnostics II-73

Triad Acquires Four Radiopharmaceutical Companies II-73

Triad Isotopes Acquires Regional Nuclear Pharmacies II-74

Triad Isotopes Merges with Diversified Pharmacy Group II-74

Molecular Insight Pharmaceuticals Acquires Radiopharmaceutical

Facility In Texas II-74

GE Healthcare to Shelf Production of Products with Short-Lived

Radioisotopes II-74

Draxis Health Files ANDA to Market Cardiac Imaging Agent II-74

Cell Therapeutics Acquires Zevalin(R) Lymphoma Drug II-74

Premier Signs Contracts with Mallinckrodt, Agfa, Berlex II-74

ADMD Announces Patent Licensing for Preparing Actinium-225 II-75

Bayer Schering Exercises Rights to License Avid's 18-F AV1/ZK

Compound II-75

Covidien Signs Agreement with BioSynthema for Cancer Treatment

Technology II-75

IBA Signs Contract to Supply Cyclone(R) 30 to Indian DAE II-76

MDS Nordion, Ottawa University to Establish Molecular Imaging

Center of Excellence II-76

STC.UNM, NuView Sign Exclusive Commercialization and

Distribution Deal II-76

Bracco, ImaRx Ink Cross Licensing Deal II-76

GE Healthcare Signs Exclusive Distribution Deal with Draximage II-76

DRAXIMAGE, Med Discovery Form Research Collaboration II-77

Schering Changes Corporate Identity to Bayer Schering Pharma AG II-77

IBA Establishes New Radiopharmaceuticals Production Facility II-77

IBA Receives Approval for Production of Radiopharmaceuticals

at UK Facility II-77

IBA Establishes Production and R&D Center in Belgium II-77

MDS Nordion to Expand Medical Imaging Agent Production in Europe II-78

MDS Nordion, Avid Radiopharmaceuticals Ink Collaborative

Agreement II-78

MDS Nordion Establishes Centers of Excellence for TheraSphere(R)

in Europe II-78

Peregrine Opens Facility in China II-78

GE Healthcare Receives Approval for First Radiopharmacy

Facility in India II-79

Nuclear Research Center of Iran Announces Production of

technetium-99m II-79

MDS Nordion Begins Clinical Trials For TheraSphere(R) II-79

Dow Offers ChelaMed(SM) Radiopharmaceutical Services II-79

Eckert & Ziegler Sets Up New Company For Radiopharmaceutical

Development II-79

IBA Molecular Collaborates with WILEX AG II-79

IBA Molecular Kicks Off Radiopharmaceutical Facility in India II-80

Cardinal Health Acquires Syncor International II-80

7. Focus on Select Players II-81

Actinium Pharmaceuticals, Inc. (US) II-81

Advanced Medical Isotope Corporation (US) II-81

Alseres Pharmaceuticals, Inc (US) II-81

Bayer HealthCare Pharmaceuticals (US) II-81

Bio-Nucleonics, Inc. (US) II-82

Bracco Diagnostics, Inc. (US) II-82

Cardinal Health, Inc (US) II-82

Cellectar, LLC. (US) II-83

Cell Therapeutics, Inc. (US) II-83

Covidien Imaging Solutions (US) II-83

Cytogen Corporation (US) II-83

Draximage Inc (Canada) II-84

GE Healthcare Limited (UK) II-84

GlaxoSmithKline Plc (UK) II-84

IBA Molecular North America, Inc. (US) II-85

Immunomedics, Inc. (US) II-85

Kimberly-Clark, Inc. (US) II-85

Lantheus Medical Imaging, Inc (US) II-86

MDS Nordion (Canada) II-86

Molecular Insight Pharmaceuticals, Inc. (US) II-86

Peregrine Pharmaceuticals, Inc. (US) II-86

PETNET Pharmaceuticals, Inc. (US) II-87

Pharmalucence, Inc. (US) II-87

Triad Isotopes, Inc. (US) II-87

III. COMPETITIVE LANDSCAPE

To order this report:

US and European Radiopharmaceuticals Market

http://www.reportlinker.com/p0109914/US-and-European-Radiopharmaceuticals-Market.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Reportlinker Adds World Cancer Therapies Market Report
2. Reportlinker Adds Infusion Pumps Report
3. Reportlinker Adds Autoimmune Disease Therapeutics Report
4. Reportlinker Adds Spinal Surgery Report
5. Reportlinker Adds Lung Cancer Therapeutics Report
6. Reportlinker Adds Mechanical Ventilators Report
7. Reportlinker Adds Gastrointestinal Endoscopy Devices Report
8. Reportlinker Adds Bariatric (Obesity) Surgical Devices Report
9. Reportlinker Adds Prescription Drugs Report
10. Reportlinker Adds Liver Disease Treatments: The Global Market Report
11. Reportlinker Adds Cosmetic Surgery Markets: Products and Services Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... Stephanie Hebert Insurance Agency, serving families of ... charity campaign. As part of their ongoing community involvement program, funds are now ... children deserve a voice, and in the spirit of neighbors helping neighbors in ...
(Date:2/8/2016)... , ... February 08, 2016 , ... A man who has struggled to quit smoking, ... Laser Therapy , was determined to find solutions to his problems – and he did. ... Digest is ready to introduce his breakthrough inventions to the world and better people's ...
(Date:2/8/2016)... York, NY (PRWEB) , ... February 08, 2016 , ... ... are too much to handle, you are not alone. According to the Center for ... include heart disease, stroke, type 2 diabetes and certain types of cancer, some of ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, ... report, "Cardiovascular Surgery Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
(Date:2/8/2016)... 2016  Labvantage Lx, a newcomer to the ... sexual enhancement product, EnduramenT. Setting a new standard ... a patented biomedical breakthrough molecule that promotes the ... responsible for many biological functions including erectile function. ... Forgoing the use of prescription medications, scientists working ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology: